- Home
- GNLX vs RVPH Comparison
GNLX vs RVPH Comparison
Compare GNLX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- RVPH
- Stock Information
- Founded
- GNLX 2001
- RVPH 2006
- Country
- GNLX United States
- RVPH United States
- Employees
- GNLX 24
- RVPH N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- RVPH Health Care
- Exchange
- GNLX Nasdaq
- RVPH Nasdaq
- Market Cap
- GNLX 112.8M
- RVPH 32.8M
- IPO Year
- GNLX 2023
- RVPH N/A
- Fundamental
- Price
- GNLX $3.09
- RVPH $0.37
- Analyst Decision
- GNLX Strong Buy
- RVPH Strong Buy
- Analyst Count
- GNLX 4
- RVPH 5
- Target Price
- GNLX $17.75
- RVPH $9.00
- AVG Volume (30 Days)
- GNLX 137.5K
- RVPH 2.6M
- Earning Date
- GNLX 08-13-2025
- RVPH 08-13-2025
- Dividend Yield
- GNLX N/A
- RVPH N/A
- EPS Growth
- GNLX N/A
- RVPH N/A
- EPS
- GNLX N/A
- RVPH N/A
- Revenue
- GNLX N/A
- RVPH N/A
- Revenue This Year
- GNLX N/A
- RVPH N/A
- Revenue Next Year
- GNLX N/A
- RVPH N/A
- P/E Ratio
- GNLX N/A
- RVPH N/A
- Revenue Growth
- GNLX N/A
- RVPH N/A
- 52 Week Low
- GNLX $1.60
- RVPH $0.30
- 52 Week High
- GNLX $5.89
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- GNLX 56.10
- RVPH 30.28
- Support Level
- GNLX $2.75
- RVPH $0.35
- Resistance Level
- GNLX $3.17
- RVPH $0.83
- Average True Range (ATR)
- GNLX 0.24
- RVPH 0.07
- MACD
- GNLX -0.00
- RVPH -0.04
- Stochastic Oscillator
- GNLX 56.94
- RVPH 11.32
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.